Cargando…

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial

Background Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence the outcome of endocrine therapy for breast cancer. Methods A validated immunohistochemical assay for aromatase was applied to samples from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellis, Matthew J., Miller, William R., Tao, Yu, Evans, Dean B., Chaudri Ross, Hilary A., Miki, Yasuhiro, Suzuki, Takashi, Sasano, Hironobu
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2008
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696016/ https://www.ncbi.nlm.nih.gov/pubmed/18941892 http://dx.doi.org/10.1007/s10549-008-0161-8

Ejemplares similares

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Epitope Characterization of an Aromatase Monoclonal Antibody Suitable for the Assessment of Intratumoral Aromatase Activity
por: Hong, Yanyan, et al.
Publicado: (2009)

IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients
por: Palmieri, Carlo, et al.
Publicado: (2017)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017)

Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts
por: Miki, Yasuhiro, et al.
Publicado: (2017)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Aromatase in human liver and its diseases
por: Hata, Shuko, et al.
Publicado: (2013)

Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
por: Reis, Joana, et al.
Publicado: (2020)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
por: Iwata, Hiroji, et al.
Publicado: (2018)

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer
por: Lykkesfeldt, Anne E, et al.
Publicado: (2009)

Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial
por: Reis, Joana, et al.
Publicado: (2021)

Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
por: Bahrami, Nazli, et al.
Publicado: (2021)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2017)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
por: Iwata, Hiroji, et al.
Publicado: (2013)

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
por: Chen, Tom Wei-Wu, et al.
Publicado: (2023)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study
por: Donders, Gilbert, et al.
Publicado: (2014)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
por: Masuda, Norikazu, et al.
Publicado: (2021)

The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions
por: Beugels, J., et al.
Publicado: (2019)

The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery
por: Nussbaumer, R. L., et al.
Publicado: (2022)

SAT-024 Adipose Specific Inactivation of Aromatase is Sufficient to Cause Adiposity and Impaired Glucose Tolerance in Mice
por: Oz, Orhan, et al.
Publicado: (2019)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer
por: Skarping, Ida, et al.
Publicado: (2021)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer
por: Zhou, Yijun, et al.
Publicado: (2016)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2020)

Visualization of the protein–protein interactions of hormone receptors in hormone-dependent cancer research
por: Iwabuchi, Erina, et al.
Publicado: (2022)

Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study
por: Pan, Yiqi, et al.
Publicado: (2018)

Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?
por: Schaefgen, Benedikt, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uvtpe04oc1449pj1ui5373bkcg